Research use only · EU-warehoused · COA on every batch · HPLC ≥99% · Shipment 2–5 days
Log in Register
Home/ Catalogue/ Encapsulated Compounds/ Tesofensine Capsules
In stock
Tesofensine Capsules

Tesofensine Capsules

Lyophilised · ≥98% (HPLC) ·

Quantity Volume discounts auto-applied
Custom quantity
1

Supplied lyophilised. Reconstitution typically uses bacteriostatic water.

Independently third-party tested · COA on every batch · 48h EU dispatch
[01]

Overview

Tesofensine is a presynaptic monoamine reuptake inhibitor that blocks the reuptake of serotonin, dopamine, and noradrenaline, originally developed as a neurological compound and subsequently investigated in metabolic and appetite-regulation research models. CAS 195875-84-4; molecular formula C17H23Cl2NO; molecular weight 328.3 g/mol. Supplied as encapsulated compound. For laboratory research use only; not for human or veterinary use.

The brain regulates appetite and energy balance through a trio of chemical messengers — serotonin, noradrenaline and dopamine — and most experimental tools touch only one of them. Tesofensine (NS2330) is different: it is a small-molecule triple monoamine reuptake inhibitor, a research compound that engages all three transporters at once, which is precisely why it has become a recurring subject in central-nervous-system and energy-balance neuroscience.

One molecule, three transporters. By inhibiting the serotonin, noradrenaline and dopamine reuptake transporters in parallel, Tesofensine has been used in animal models to probe how converging monoamine signalling shapes hypothalamic circuits and feeding behaviour (Perez et al., 2024; Hansen et al., 2013). It belongs to the broader class of centrally acting compounds long studied in appetite and metabolic neuroscience (Coulter et al., 2018).

What the research explores. Across cell-culture and animal systems, Tesofensine has been investigated along several converging lines:

  • Monoamine-transporter pharmacology — characterised for its triple-reuptake-inhibition profile and dopamine-transporter engagement in mechanistic studies (Appel et al., 2014; Li et al., 2025).
  • Hypothalamic & appetite-circuit models — examined for effects on GABAergic hypothalamic neurons and feeding-related behaviour in rodents (Perez et al., 2024; Hansen et al., 2013).
  • Energy-balance & CNS behavioural research — explored in animal paradigms of appetite suppression and stereotyped behaviour (Lopez et al., 2025; Korte et al., 2015).

The activity described here is drawn from in-vitro and animal studies; it characterises biological behaviour in experimental models and does not establish efficacy or safety in humans. Full citations are listed under the Scientific References tab.

Physicochemical profile. CAS No. 195875-84-4 · Molecular formula C17H23Cl2NO · Molecular weight 328.29 g/mol · Appearance: White to off-white powder · Solubility: Soluble in DMSO; sparingly in water.

Specification & quality. Each bottle contains 30 HPMC (vegan) capsules, each providing 500mcg of Tesofensine at ≥98% (HPLC). Encapsulated — no reconstitution required. Every batch is independently third-party tested, and a Certificate of Analysis (COA) is available. Store at room temperature, protect from light and moisture; shelf life 24 months from the manufacture date. EU warehoused.

This product is intended for laboratory research use only (RUO). It is not a drug, food, cosmetic, or dietary supplement, and is not for human or veterinary use, ingestion, or diagnostic application. Handling is restricted to qualified research professionals operating in an appropriately equipped laboratory.

Supplied for in-vitro laboratory research use only (RUO). Not a drug, food or supplement; not for human or veterinary use.

[04]

Quality & COA

Certificate of Analysis
Lot-specific COA with every order

Certificate of Analysis — lot-specific COA ships with every order and is available on request.

Each lot is tested by an independent third-party laboratory for identity (mass spectrometry) and purity (HPLC). The Certificate of Analysis for your specific batch ships with the order and is available on request — no house data, no exceptions.

HPLC purity
≥98% (HPLC)
Method
HPLC + MS
Endotoxin
Reported
[02]

Data Sheet

CAS number195875-84-4
Molecular formulaC17H23Cl2NO
Molecular weight328.29
Purity≥98% (HPLC)
Physical formWhite to off-white powder
Quantity30 capsules
SolubilitySoluble in DMSO; sparingly in water
StorageStore at room temperature, protect from light and moisture
ReconstitutionEncapsulated — no reconstitution required.
Shelf life24 months from manufacture date
Dose per capsule500mcg
Capsule materialHPMC (Vegan)
OriginEU · Slovakia
ClassificationResearch use only
[03]

Scientific References

01 Li X, Bello NT Anorectic state of obesity medications in the United States. Are leaner times ahead?. Expert opinion on pharmacotherapy. 2020;21(2):167-172. PMID: 31762335. doi:10.1080/14656566.2019.1692815. PubMed 02 Jeepipalli SPK, Du B, Sabitaliyevich UY, Xu B New insights into potential nutritional effects of dietary saponins in protecting against the development of obesity. Food chemistry. 2020;318:126474. PMID: 32151922. doi:10.1016/j.foodchem.2020.126474. PubMed 03 Coulter AA, Rebello CJ, Greenway FL Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs. 2018;78(11):1113-1132. PMID: 30014268. doi:10.1007/s40265-018-0946-y. PubMed 04 Srivastava G, Apovian C Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. Current obesity reports. 2018;7(2):147-161. PMID: 29504049. doi:10.1007/s13679-018-0300-4. PubMed 05 Maksimov ML, Svistunov AA, Tarasov VV, Chubarev VN, Ávila-Rodriguez M, Barreto GE et al. Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome. Current pharmaceutical design. 2016;22(7):895-903. PMID: 26648466. doi:10.2174/1381612822666151209153047. PubMed 06 Korte SM, Prins J, Krajnc AM, Hendriksen H, Oosting RS, Westphal KG et al. The many different faces of major depression: it is time for personalized medicine. European journal of pharmacology. 2015;753:88-104. PMID: 25592320. doi:10.1016/j.ejphar.2014.11.045. PubMed 07 Li Y, Meng Y, Li N, Zhao J, Li R, Bai Q et al. Structural basis for pharmacotherapeutic action of triple reuptake inhibitors. Nature communications. 2025;17(1):61. PMID: 41392177. doi:10.1038/s41467-025-66670-3. PubMed 08 Lopez A, Gil-Lievana E, Gutierrez R Sex-specific effects of appetite suppressants on stereotypy in rats. PloS one. 2025;20(6):e0325067. PMID: 40554466. doi:10.1371/journal.pone.0325067. PubMed 09 Perez CI, Luis-Islas J, Lopez A, Diaz X, Molina O, Arroyo B et al. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PloS one. 2024;19(4):e0300544. PMID: 38656972. doi:10.1371/journal.pone.0300544. PubMed 10 Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. European journal of endocrinology. 2022;186(6):687-700. PMID: 35294397. doi:10.1530/EJE-21-0972. PubMed 11 Appel L, Bergström M, Buus Lassen J, Långström B Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2014;24(2):251-61. PMID: 24239329. doi:10.1016/j.euroneuro.2013.10.007. PubMed 12 Hansen HH, Jensen MM, Overgaard A, Weikop P, Mikkelsen JD Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacology, biochemistry, and behavior. 2013;110:265-71. PMID: 23932919. doi:10.1016/j.pbb.2013.07.018. PubMed 13 Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2013;381(9873):1167. PMID: 23561987. doi:10.1016/S0140-6736(13)60778-3. PubMed 14 Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM Under-reporting of adverse effects of tesofensine. Lancet (London, England). 2013;382(9887):127. PMID: 23849924. doi:10.1016/S0140-6736(13)61563-9. PubMed 15 Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, Lassen JB, Hansen HH Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring, Md.). 2013;21(5):985-92. PMID: 23784901. doi:10.1002/oby.20122. PubMed

References are illustrative of the research literature surrounding this compound. All claims relate to in-vitro and animal models only.

[05]

FAQ

Tesofensine (NS2330) is a small-molecule triple monoamine reuptake inhibitor that engages the serotonin, noradrenaline and dopamine transporters, studied in central-nervous-system and energy-balance models (Appel et al., 2014). It is used in animal and in-vitro research to probe converging monoamine signalling. Condor Research supplies it strictly as a Research Use Only reference compound, never for human or veterinary use, and it is geo-restricted at checkout.

Triple reuptake inhibitors are a chemical class studied for simultaneous action on three monoamine transporters, and structural work continues to map how such compounds bind their targets (Li et al., 2025). Tesofensine is one of the most-referenced members and is frequently used as a probe of dopamine-transporter occupancy in mechanistic studies (Appel et al., 2014). It is supplied only as a research-use-only reference compound for in vitro and animal work.

Many centrally acting compounds studied in appetite neuroscience target a single neurotransmitter system, whereas Tesofensine is distinguished by acting on three monoamine transporters in parallel within hypothalamic circuit models (Perez et al., 2024; Coulter et al., 2018). This multi-transporter profile makes it a specific tool for energy-balance circuit questions. It is offered strictly for laboratory research use only.

They operate in completely different domains. Tesofensine is a CNS-acting monoamine-transporter inhibitor studied in appetite and energy-balance neuroscience (Hansen et al., 2013), while 5-Amino-1MQ is an NNMT enzyme inhibitor studied in peripheral NAD+/SAM metabolism. They answer unrelated research questions and are not interchangeable. Both are supplied only as research-use-only reference compounds, never for human or veterinary use.

Tesofensine availability is limited by region because its regulatory status varies between jurisdictions, so checkout applies geo-restriction and the buyer is responsible for verifying that import of this Research Use Only reference compound is permitted where they are located. It is supplied under a strict RUO framework, never as a medicine, supplement or product for human or veterinary use. For eligibility questions, contact info@condorresearch.com.

Yes. Condor Research supplies Tesofensine strictly as a Research Use Only reference compound to professionals and institutions, not as a medicine, supplement or product for human or veterinary use. Because it is geo-restricted, buyers are responsible for confirming import legality in their own country before ordering. Questions: info@condorresearch.com.

The capsule is a pre-weighed solid format that standardises the quantity of reference compound per unit, simplifying bench handling and inventory for laboratory work. Each is an HPMC (vegan) capsule containing the powder — no reconstitution is required, and the format does not imply or permit any form of consumption. For laboratory research use only. Not for human or veterinary use.

Each bottle contains 30 HPMC (vegan) capsules, with 500mcg of Tesofensine per capsule at ≥98% HPLC purity, and every batch is independently third-party tested. The per-capsule figure denotes only the pre-weighed quantity of reference compound for laboratory measurement — this product is for research use only and not for human or veterinary use, ingestion, or diagnostic application.

Tesofensine has CAS No. 195875-84-4, a molecular formula of C17H23Cl2NO and a molecular weight of 328.29 g/mol. It presents as a white to off-white powder, soluble in DMSO and sparingly soluble in water. These specifications are provided for laboratory identification and research use only.

Yes. Every Tesofensine batch is tested by an independent third-party laboratory by HPLC for identity and purity (≥98%), and each lot ships with a lot-specific Certificate of Analysis. To request the COA for your batch, contact info@condorresearch.com. The material is supplied strictly for research use only.

[06]

Reviews

Leave a review
Earn 250 points for a verified review (account required).
4.7
50 verified reviews
5
78%
4
16%
3
4%
2
2%
1
0%
Apr 2026
Reproducible across batches

Third order with Condor. Batch-to-batch variation is minimal, which matters for our longitudinal work. The mono-labelled vials are easy to track.

Dr. R. Costa · Academic lab · PT Verified purchase
Mar 2026
Exactly what research needs

No marketing fluff — just characterised material with paperwork. The data sheet and CAS matched our records precisely.

J. Meijer · Biotech R&D · NL Verified purchase
Mar 2026
High purity, clear labelling

Lyophilised cake was uniform and dissolved fully. Would appreciate a digital COA portal, but the PDF on request worked fine.

Dr. A. Bianchi · University · IT Verified purchase
Feb 2026
Trustworthy supplier

Identity by MS confirmed in our facility. Communication around storage and handling was precise and professional.

K. Wójcik · Research group · PL Verified purchase

Related compounds